BioMarin Buys Alesta for Rare Bone Disease Drug

BioMarin is a big name in medicines for rare diseases. Now, the company is growing even more. BioMarin just announced it will buy Alesta Therapeutics for $275 million. This deal helps BioMarin get closer to a new medicine.

Alesta Therapeutics has a special drug. This drug could treat a rare bone disease. It focuses on skeletal conditions. These are problems with bones and joints. This new drug could bring much-needed help to patients.

This purchase shows BioMarin's focus. They want to find treatments for diseases that do not have many options. The $275 million upfront payment secures this important drug candidate. It boosts BioMarin's unit that works on rare bone issues.

This move could mean new hope for families. It offers a potential path to better health. BioMarin keeps working to solve hard medical problems.

Source: CNBC